ArticleAnnals of surgical oncology2026
Hepatectomy After Progressive Disease Following Chemotherapy for Colorectal Liver Metastases: A Japanese Nationwide Cohort Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the postoperative outcomes of patients with progressive disease after systemic chemotherapy compared with those with controlled disease.
methodsThis retrospective study analyzed patients from the Colorectal Cancer Liver Metastasis Database, compiled by the Joint Committee of Liver Metastases Survey from Colorectal Cancer. Patients who received chemotherapy were categorized into complete response, partial response, stable disease, and progressive disease groups and further subdivided into resected and non-resected subgroups. Survival outcomes and prognostic factors were evaluated.
resultsThe number of patients in the complete response/partial response, stable disease, and progressive disease groups was 867, 550, and 195, respectively. Among the progressive disease group, 111 patients (57%) underwent hepatectomy. Their postoperative 5 year overall survival rate was 42.7%, which was significantly lower than that of the resected-complete response/partial response (62.0%, p<0.001) and resected-stable disease groups (55.5%; p<0.001). However, overall survival from the date of colorectal liver metastases diagnosis of the resected-progressive disease group was better than that of the non-resected-partial response group (5 year, 46.5% vs 11.4%, p<0.001). Multivariate analysis performed on the resected-progressive disease group revealed preoperative carcinoembryonic antigen (CEA) ≥100 ng/mL and metachronous colorectal liver metastases as independent predictors of poor overall survival.
conclusionsAlthough progressive disease after chemotherapy generally indicated poor prognosis, it should not be an absolute contraindication for hepatectomy. Preoperative CEA ≥100 ng/mL and metachronous colorectal liver metastases may identify a higher-risk subset and should be considered when determining surgical indications.
Indexed as
Identifiers
42542513What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.